Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Heart Failure Reviews
Published in: Heart Failure Reviews 1/2023

Open Access 14-05-2022 | Cardiomyopathy

Endomyocardial biopsy in the clinical context: current indications and challenging scenarios

Authors: Aldostefano Porcari, Chiara Baggio, Enrico Fabris, Marco Merlo, Rossana Bussani, Andrea Perkan, Gianfranco Sinagra

Published in: Heart Failure Reviews | Issue 1/2023

Login to get access

Abstract

Endomyocardial biopsy (EMB) is an invasive procedure originally developed for the monitoring of heart transplant rejection. Over the year, this procedure has gained a fundamental complementary role in the diagnostic work-up of several cardiac disorders, including cardiomyopathies, myocarditis, drug-related cardiotoxicity, amyloidosis, other infiltrative and storage disorders, and cardiac tumours. Major advances in EMB equipment and techniques for histological analysis have significantly improved diagnostic accuracy of EMB. In recent years, advanced imaging modalities such as echocardiography with three-dimensional and myocardial strain analysis, cardiac magnetic resonance and bone scintigraphy have transformed the non-invasive approach to diagnosis and prognostic stratification of several cardiac diseases. Therefore, it emerges the need to re-define the current role of EMB for diagnostic work-up and management of cardiovascular diseases. The aim of this review is to summarize current knowledge on EMB in light of the most recent evidences and to discuss current indications, including challenging scenarios encountered in clinical practice.
Appendix
Available only for authorised users
Literature
1.
Sakakibara S, Konno S (1962) Endomyocardial biopsy. Jpn Heart J 3:537–543CrossRef
2.
Sinagra G, Porcari A, Fabris E, Merlo M (2021) Standardizing the role of endomyocardial biopsy in current clinical practice worldwide. Eur J Heart Fail 23:1995–1998CrossRef
3.
Porcari A, De LA, Grigoratos C, Biondi F, Faganello G, Vitrella G, Nucifora G, Aquaro GD, Merlo M, Sinagra G (2022) Arrhythmic risk stratification by cardiac magnetic resonance tissue characterization: disclosing the arrhythmic substrate within the heart muscle. Heart Fail Rev 27:49–69CrossRef
4.
Friedrich MG, Sechtem U, Schulz-Menger J, Holmvang G, Alakija P, Cooper LT, White JA, Abdel-Aty H, Gutberlet M, Prasad S, Aletras A, Laissy J-P, Paterson I, Filipchuk NG, Kumar A, Pauschinger M, Liu P (2009) Cardiovascular magnetic resonance in myocarditis: a JACC white paper. J Am Coll Cardiol 53:1475–1487CrossRef
5.
Ferreira VM, Schulz-Menger J, Holmvang G, Kramer CM, Carbone I, Sechtem U, Kindermann I, Gutberlet M, Cooper LT, Liu P, Friedrich MG (2018) Cardiovascular magnetic resonance in nonischemic myocardial inflammation: expert recommendations. J Am Coll Cardiol 72:3158–3176CrossRef
6.
Fischer K, Obrist SJ, Erne SA, Stark AW, Marggraf M, Kaneko K, Guensch DP, Huber AT, Greulich S, Aghayev A, Steigner M, Blankstein R, Kwong RY, Gräni C (2020) Feature tracking myocardial strain incrementally improves prognostication in myocarditis beyond traditional CMR imaging features. JACC Cardiovasc Imaging 13:1891–1901CrossRef
7.
Porcari A, Merlo M, Crosera L, Stolfo D, Barbati G, Biondi F, Angelis G De, Paldino A, Pagnan L, Belgrano M, Cova MA, Pinamonti B, Vitrella G, Sinagra G (2020) Strain analysis reveals subtle systolic dysfunction in confirmed and suspected myocarditis with normal LVEF. A cardiac magnetic resonance study. Clin Res Cardiol 109:869–880
8.
Tschöpe C, Ammirati E, Bozkurt B, Caforio ALP, Cooper LT, Felix SB, Hare JM, Heidecker B, Heymans S, Hübner N, Kelle S, Klingel K, Maatz H, Parwani AS, Spillmann F, Starling RC, Tsutsui H, Seferovic P, Van LS (2021) Myocarditis and inflammatory cardiomyopathy: current evidence and future directions. Nat Rev Cardiol 18:169–193CrossRef
9.
Seferović PM, Tsutsui H, McNamara DM, Ristić AD, Basso C, Bozkurt B, Cooper LTJ, Filippatos G, Ide T, Inomata T, Klingel K, Linhart A, Lyon AR, Mehra MR, Polovina M, Milinković I, Nakamura K, Anker SD, Veljić I, Ohtani T, Okumura T, Thum T, Tschöpe C, Rosano G, Coats AJS, Starling RC (2021) Heart failure association of the ESC, heart failure society of America and japanese heart failure society position statement on endomyocardial biopsy. Eur J Heart Fail 23:854–871CrossRef
10.
Leone O, Veinot JP, Angelini A, Baandrup UT, Basso C, Berry G, Bruneval P, Burke M, Butany J, Calabrese F, D’Amati G, Edwards WD, Fallon JT, Fishbein MC, Gallagher PJ, Halushka MK, McManus B, Pucci A, Rodriguez ER, Saffitz JE, Sheppard MN, Steenbergen C, Stone JR, Tan C, Thiene G, van der Wal AC, Winters GL (2012) 2011 Consensus statement on endomyocardial biopsy from the association for european cardiovascular pathology and the society for cardiovascular pathology. Cardiovasc Pathol 21:245–274CrossRef
11.
Cooper LT, Baughman KL, Feldman AM, Frustaci A, Jessup M, Kuhl U, Levine GN, Narula J, Starling RC, Towbin J, Virmani R (2007) The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the american heart association, the american college of cardiology, and the european society of cardiology. Endorsed by the heart failure society o. J Am Coll Cardiol 50:1914–1931
12.
Caforio ALP, Calabrese F, Angelini A, Tona F, Vinci A, Bottaro S, Ramondo A, Carturan E, Iliceto S, Thiene G, Daliento L (2007) A prospective study of biopsy-proven myocarditis: prognostic relevance of clinical and aetiopathogenetic features at diagnosis. Eur Heart J 28:1326–1333CrossRef
13.
Sinagra G, Porcari A, Gentile P, Artico J, Fabris E, Bussani R, Merlo M (2021) Viral presence-guided immunomodulation in lymphocytic myocarditis: an update. Eur J Heart Fail 23:211–216CrossRef
14.
Ammirati E, Cipriani M, Moro C, Raineri C, Pini D, Sormani P, Mantovani R, Varrenti M, Pedrotti P, Conca C, Mafrici A, Grosu A, Briguglia D, Guglielmetto S, Perego GB, Colombo S, Caico SI, Giannattasio C, Maestroni A, Carubelli V, Metra M, Lombardi C, Campodonico J, Agostoni P, Peretto G, Scelsi L, Turco A, Di TG, Campana C, Belloni A et al (2018) Clinical presentation and outcome in a contemporary cohort of patients with acute myocarditis. Circulation 138:1088–1099CrossRef
15.
Tavazzi G, Pellegrini C, Maurelli M, Belliato M, Sciutti F, Bottazzi A, Sepe PA, Resasco T, Camporotondo R, Bruno R, Baldanti F, Paolucci S, Pelenghi S, Iotti GA, Mojoli F, Arbustini E (2020) Myocardial localization of coronavirus in COVID-19 cardiogenic shock. Eur J Heart Fail 22:911–915CrossRef
16.
Yilmaz A, Kindermann I, Kindermann M, Mahfoud F, Ukena C, Athanasiadis A, Hill S, Mahrholdt H, Voehringer M, Schieber M, Klingel K, Kandolf R, Böhm M, Sechtem U (2010) Comparative evaluation of left and right ventricular endomyocardial biopsy. Circulation 122:900–909CrossRef
17.
Chimenti C, Frustaci A (2013) Contribution and risks of left ventricular endomyocardial biopsy in patients with cardiomyopathies: a retrospective study over a 28-year period. Circulation 128:1531–1541CrossRef
18.
Schulz E, Jabs A, Gori T, Hink U, Sotiriou E, Tschöpe C, Schultheiss H-P, Münzel T, Wenzel P (2015) Feasibility and safety of left ventricular endomyocardial biopsy via transradial access: technique and initial experience. Catheter Cardiovasc Interv Off J Soc Card Angiogr Interv 86:761–765CrossRef
19.
Schäufele TG, Spittler R, Karagianni A, Ong P, Klingel K, Kandolf R, Mahrholdt H, Sechtem U (2015) Transradial left ventricular endomyocardial biopsy: assessment of safety and efficacy. Clin Res Cardiol 104:773–781CrossRef
20.
Göbel S, Schwuchow-Thonke S, Jansen T, Karbach S, Emrich T, Gori T, Knies F, Schulz E, Münzel T, Keller K, Wenzel P (2020) Safety of transradial and transfemoral left ventricular compared with transfemoral right ventricular endomyocardial biopsy. ESC Hear Fail 7:4015–4023CrossRef
21.
Choudhury T, Lurz P, Schäufele TG, Menezes MN, Lavi S, Tzemos N, Hartung P, Stiermaier T, Makino K, Bertrand OF, Gilchrist IC, Mamas MA, Bagur R (2019) Radial versus femoral approach for left ventricular endomyocardial biopsy. EuroIntervention J Eur Collab with Work Gr Interv Cardiol Eur Soc Cardiol 15:678–684
22.
Caforio ALP, Pankuweit S, Arbustini E, Basso C, Gimeno-Blanes J, Felix SB, Fu M, Helio T, Heymans S, Jahns R, Klingel K, Linhart A, Maisch B, McKenna W, Mogensen J, Pinto YM, Ristic A, Schultheiss H-P, Seggewiss H, Tavazzi L, Thiene G, Yilmaz A, Charron P, Elliott PM (2013) Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the european society of cardiology working group on myocardial and pericardial diseases. Eur Heart J 34(2636–2648):2648a–2648d
23.
Bennett MK, Gilotra NA, Harrington C, Rao S, Dunn JM, Freitag TB, Halushka MK, Russell SD (2013) Evaluation of the role of endomyocardial biopsy in 851 patients with unexplained heart failure from 2000–2009. Circ Hear Fail 6:676–684CrossRef
24.
Sinagra G, Anzini M, Pereira NL, Bussani R, Finocchiaro G, Bartunek J, Merlo M (2016) Myocarditis in clinical practice. Mayo Clin Proc 91:1256–1266CrossRef
25.
McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri H, Butler J, Čelutkienė J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F et al (2021) 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 42:3599–3726CrossRef
26.
Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A, Burazor I, Caforio ALP, Damy T, Eriksson U, Fontana M, Gillmore JD, Gonzalez-Lopez E, Grogan M, Heymans S, Imazio M, Kindermann I, Kristen AV, Maurer MS, Merlini G, Pantazis A, Pankuweit S, Rigopoulos AG, Linhart A (2021) Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC working group on myocardial and pericardial diseases. Eur Heart J 42:1554–1568CrossRef
27.
Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS (2019) Transthyretin amyloid cardiomyopathy. J Am Coll Cardiol 73:2872–2891CrossRef
28.
Porcari A, Merlo M, Rapezzi C, Sinagra G (2020) Transthyretin amyloid cardiomyopathy: an uncharted territory awaiting discovery. Eur J Intern Med 82:7–15CrossRef
29.
Pollack A, Kontorovich AR, Fuster V, Dec GW (2015) Viral myocarditis–diagnosis, treatment options, and current controversies. Nat Rev Cardiol 12:670–680CrossRef
30.
Porcari A, De AG, Romani S, Paldino A, Artico J, Cannatà A, Gentile P, Pinamonti B, Merlo M, Sinagra G (2019) Current diagnostic strategies for dilated cardiomyopathy: a comparison of imaging techniques. Expert Rev Cardiovasc Ther 17:53–63CrossRef
31.
Porcari A, Bussani R, Merlo M, Varrà GG, Pagura L, Rozze D, Sinagra G (2021) Incidence and characterization of concealed cardiac amyloidosis among unselected elderly patients undergoing post-mortem examination. Front Cardiovasc Med 8:749523
32.
Limongelli G, Monda E, Tramonte S, Gragnano F, Masarone D, Frisso G, Esposito A, Gravino R, Ammendola E, Salerno G, Rubino M, Caiazza M, Russo M, Calabrò P, Elliott PM, Pacileo G (2020) Prevalence and clinical significance of red flags in patients with hypertrophic cardiomyopathy. Int J Cardiol 299:186–191CrossRef
33.
Porcari A, Pagura L, Longo F, Sfriso E, Barbati G, Murena L, Longo E, Ramella V, Arnež ZM, Rapezzi C, Merlo M, Sinagra G (2022) Prognostic significance of unexplained left ventricular hypertrophy in patients undergoing carpal tunnel surgery. ESC Hear Fail 9:751–760CrossRef
34.
Arad M, Maron BJ, Gorham JM, Johnson WHJ, Saul JP, Perez-Atayde AR, Spirito P, Wright GB, Kanter RJ, Seidman CE, Seidman JG (2005) Glycogen storage diseases presenting as hypertrophic cardiomyopathy. N Engl J Med 352:362–372CrossRef
35.
Vergaro G, Aimo A, Barison A, Genovesi D, Buda G, Passino C, Emdin M (2020) Keys to early diagnosis of cardiac amyloidosis: red flags from clinical, laboratory and imaging findings. Eur J Prev Cardiol 27:1806–1815CrossRef
36.
Kremastinos DT, Farmakis D (2011) Iron overload cardiomyopathy in clinical practice. Circulation 124:2253–2263CrossRef
37.
Bussani R, Castrichini M, Restivo L, Fabris E, Porcari A, Ferro F, Pivetta A, Korcova R, Cappelletto C, Manca P, Nuzzi V, Bessi R, Pagura L, Massa L, Sinagra G (2020) Cardiac tumors: diagnosis, prognosis, and treatment. Curr Cardiol Rep 22:169CrossRef
38.
Stewart S, Winters GL, Fishbein MC, Tazelaar HD, Kobashigawa J, Abrams J, Andersen CB, Angelini A, Berry GJ, Burke MM, Demetris AJ, Hammond E, Itescu S, Marboe CC, McManus B, Reed EF, Reinsmoen NL, Rodriguez ER, Rose AG, Rose M, Suciu-Focia N, Zeevi A, Billingham ME (2005) Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Hear lung Transplant Off Publ Int Soc Hear Transplant 24:1710–1720CrossRef
39.
Crespo-Leiro MG, Zuckermann A, Bara C, Mohacsi P, Schulz U, Boyle A, Ross HJ, Parameshwar J, Zakliczyński M, Fiocchi R, Stypmann J, Hoefer D, Lehmkuhl H, Deng MC, Leprince P, Berry G, Marboe CC, Stewart S, Tazelaar HD, Baron HM, Coleman I-C, Vanhaecke J (2012) Concordance among pathologists in the second cardiac allograft rejection gene expression observational study (CARGO II). Transplantation 94:1172–1177CrossRef
40.
Pham MX, Teuteberg JJ, Kfoury AG, Starling RC, Deng MC, Cappola TP, Kao A, Anderson AS, Cotts WG, Ewald GA, Baran DA, Bogaev RC, Elashoff B, Baron H, Yee J, Valantine HA (2010) Gene-expression profiling for rejection surveillance after cardiac transplantation. N Engl J Med 362:1890–1900CrossRef
41.
Purewal S, Moayedi Y, Runeckles K, Fan C, Gordon J, Henricksen EJ, Oro G, Shudo Y, Khush KK, Teuteberg J (2020) Are two tests better than one? Combining donor derived cell-free DNA and gene expression profiling for non-invasive surveillance after heart transplantation. J Hear Lung Transplant 39:S71CrossRef
42.
Howlett JG, Crespo-Leiro MG (2021) The international endomyocardial biopsy position paper: a basis for integration into modern clinical practice. J Card Fail S1071–9164(21)00261-X
43.
Baggio C, Gagno G, Porcari A, Paldino A, Artico J, Castrichini M, Dal Ferro M, Bussani R, Merlo M (2021) Myocarditis: which role for genetics? Curr Cardiol Rep 23:58CrossRef
44.
Blanco-Domínguez R, Sánchez-Díaz R, la Fuente H, de, Jiménez-Borreguero LJ, Matesanz-Marín A, Relaño M, Jiménez-Alejandre R, Linillos-Pradillo B, Tsilingiri K, Martín-Mariscal ML, Alonso-Herranz L, Moreno G, Martín-Asenjo R, García-Guimaraes MM, Bruno KA, Dauden E, González-Álvaro I, Villar-Guimerans LM, Martínez-León A, Salvador-Garicano AM, Michelhaugh SA, Ibrahim NE, Januzzi JL, Kottwitz J, Iliceto S, Plebani M, Basso C, Baritussio A, Seguso M, Marcolongo R et al (2021) A novel circulating microRNA for the detection of acute myocarditis. N Engl J Med 384:2014–2027
45.
Lurz P, Luecke C, Eitel I, Föhrenbach F, Frank C, Grothoff M, de Waha S, Rommel K-P, Lurz JA, Klingel K, Kandolf R, Schuler G, Thiele H, Gutberlet M (2016) Comprehensive cardiac magnetic resonance imaging in patients with suspected myocarditis: the MyoRacer-Trial. J Am Coll Cardiol 67:1800–1811CrossRef
46.
Zhang J, Li Y, Xu Q, Xu B, Wang H (2018) Cardiac magnetic resonance imaging for diagnosis of cardiac sarcoidosis: a meta-analysis. In: Leroyer C (ed) Can Respir J, vol 2018. p 7457369
47.
Bravo PE, Singh A, Di CMF, Blankstein R (2019) Advanced cardiovascular imaging for the evaluation of cardiac sarcoidosis. J Nucl Cardiol Off Publ Am Soc Nucl Cardiol 26:188–199
48.
Birnie DH, Nery PB, Ha AC, Beanlands RSB (2016) Cardiac sarcoidosis. J Am Coll Cardiol 68:411–421CrossRef
49.
Brownrigg J, Lorenzini M, Lumley M, Elliott P (2019) Diagnostic performance of imaging investigations in detecting and differentiating cardiac amyloidosis: a systematic review and meta-analysis. ESC Hear Fail 6:1041–1051CrossRef
50.
Fontana M, Chung R, Hawkins PN, Moon JC (2015) Cardiovascular magnetic resonance for amyloidosis. Heart Fail Rev 20:133–144CrossRef
51.
Rosengren S, Skibsted Clemmensen T, Tolbod L, Granstam S-O, Eiskjær H, Wikström G, Vedin O, Kero T, Lubberink M, Harms HJ, Flachskampf FA, Baron T, Carlson K, Mikkelsen F, Antoni G, Frost Andersen N, Hvitfeldt Poulsen S, Sörensen J (2020) Diagnostic accuracy of [(11)C]PIB positron emission tomography for detection of cardiac amyloidosis. JACC Cardiovasc Imaging 13:1337–1347CrossRef
52.
Jessup M, Abraham WT, Casey DE, Feldman AM, Francis GS, Ganiats TG, Konstam MA, Mancini DM, Rahko PS, Silver MA, Stevenson LW, Yancy CW (2009) Focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 119(14):1977–2016. https://​doi.​org/​10.​1161/​CIRCULATIONAHA.​109.​192064. Epub 2009 Mar 26. PMID: 19324967CrossRef
Metadata
Title
Endomyocardial biopsy in the clinical context: current indications and challenging scenarios
Authors
Aldostefano Porcari
Chiara Baggio
Enrico Fabris
Marco Merlo
Rossana Bussani
Andrea Perkan
Gianfranco Sinagra
Publication date
14-05-2022
Publisher
Springer US
Published in
Heart Failure Reviews / Issue 1/2023
Print ISSN: 1382-4147
Electronic ISSN: 1573-7322
DOI
https://doi.org/10.1007/s10741-022-10247-5

Other articles of this Issue 1/2023

Heart Failure Reviews 1/2023 Go to the issue

ReviewPaper

Fibroblast growth factor 21 in heart failure

ReviewPaper

Cardiac rehabilitation in heart failure with severely reduced ejection fraction: effects on mortality

ReviewPaper

PCSK9 inhibitors safely and effectively lower LDL after heart transplantation: a systematic review and meta-analysis

ReviewPaper

Cardiometabolic-based chronic disease: adiposity and dysglycemia drivers of heart failure

ReviewPaper

Primary prevention implantable cardioverter-defibrillator use in non-ischemic dilated cardiomyopathy based on arrhythmic risk stratification and left ventricular reverse remodeling prediction

ReviewPaper

Transition to heart transplantation in post-myocardial infarction ventricular septal rupture: a systematic review

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits